Recent

% | $
Quotes you view appear here for quick access.

DexCom, Inc. (DXCM) Message Board

grueler 10 posts  |  Last Activity: May 24, 2016 10:30 AM Member since: Feb 28, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ExOne Co initiated by FBR & Co. at outperform. $14.00 PT.
    I think this will prove to be too consevative.

    Sentiment: Strong Buy

  • Reply to

    Hugh short position

    by grueler May 23, 2016 3:47 PM
    grueler grueler May 23, 2016 5:00 PM Flag

    5,342,900 shares short as last reported and over 22 days to cover..

    Sentiment: Strong Buy

  • They have to be nervous

    Sentiment: Strong Buy

  • grueler by grueler Apr 28, 2016 9:32 AM Flag

    Nice research report out this morning with a $3.50 price target.

    Sentiment: Strong Buy

  • Reply to

    Shouldnt this be GREAT NEWS??

    by ametzler451 Apr 19, 2016 2:18 PM
    grueler grueler Apr 19, 2016 10:50 PM Flag

    There have been a number of questions about the false positive rate IN the USMD study and we would like to clarify. The calculation of sensitivity and specificity requires that all Cologuard negative patients undergo colonoscopy. In this actual clinical use study, NO Cologuard-negative patients underwent colonoscopy.

    While it doesn’t appear the study’s objective is designed to calculate specificity, by calculated inference and using the FDA’s conservative methodology, it would appear that the false positive rate is 6.6 percent.

    To reach this calculation, take the 347 Cologuard tests completed and subtract the 51 positive results = 296. These are the “true negatives.” To follow the FDA methodology, divide the true negatives (296) by the true negatives plus a combination of the negatives (12) and non-advanced adenomas (9). Thus 296 / 296 + (12 + 9) = 93.4% specificity.

    The conservative estimate uses the FDA-methodology for calculating specificity and assumes all the Cologuard-negatives tests were all true negatives. If we assume Cologuard missed the same proportion of advanced adenoma that were missed in DeeP-C, specificity would be 92.7% . So the range of specificity would be 92.7-93.4% even without knowing the precise number of patients who had a negative Cologuard but a positive colonoscopy.

    Please note that the calculation of a false positive rate is 1-specificity, not the percentage of negative colonoscopies after a positive Cologuard test.

    Sentiment: Strong Buy

  • New GE facility helps Western Pa. build rep as center for 3-D printing.

    Pittsburgh may have diversified beyond its industrial past, but General Electric's chief executive said the city can become a leader in 21st-century manufacturing.
    “We think Pittsburgh has the chance, not the certainty, but has the chance to be one of the four or five destinations for additive manufacturing,” said Jeff Immelt, CEO and chairman of Fairfield, Conn.-based GE. “And we wanted to be here on the ground floor.”
    Immelt was in Findlay on Tuesday to open GE's Center for Additive Technology Advancement. The 125,000-square-foot facility, larger than two football fields, will be a hub for engineers and researchers from throughout GE who will explore how to incorporate additive manufacturing, called 3-D printing, across all eight of GE's lines of business.
    Aviation, oil and gas and energy production will be a particular focus early on, but it has broader potential, said Philippe Cochet, GE's chief productivity officer.
    The Center represents a $39 million investment from GE and will employ 50 engineers and researchers by next year, executives said. Currently, 22 people work there. The company employs about 7,000 people in Pennsylvania and has locomotive plants in Grove City and Erie.
    GE executives, state officials and others attending the opening spoke of developing a local ecosystem around additive manufacturing, a process that makes solid objects by printing thin layers of plastic or metal on top of one another.
    The additive manufacturing industry surpassed $5.1 billion worldwide in 2015, up 26 percent from the year before, according to a report released Tuesday by Wohlers Associates Inc., a Fort Collins, Colo.-based manufacturing consulting firm.
    Pittsburgh is building a reputation as a center for 3-D printing. North Huntingdon-based ExOne makes 3-D printers — its machines were being used in GE's new facility. Aluminum maker Alcoa recently completed an expansion of its tech center in Upper

    Sentiment: Strong Buy

  • Reply to

    Downgrade - Really!

    by praying2tradeup Mar 28, 2016 7:55 AM
    grueler grueler Mar 28, 2016 9:50 AM Flag

    If you think “Imperial” effected the stock today, I think you give them too much credit. Who would listen to them? This morning there was a little confusion about the 8K XONE filed. I have researched it and it is nothing more than a standard 8K due to the fact that the company changed (upgraded) it’s auditors. XONE is a growing company, this is a good thing, if anything. Buy opportunity under $12.

    Sentiment: Strong Buy

  • grueler grueler Mar 28, 2016 12:09 AM Flag

    If it is so good then why does Microsoft have to force it upon people, even though they offer it for free?

    Sentiment: Strong Sell

  • grueler grueler Mar 27, 2016 11:27 PM Flag

    Hey smart guy. I have gone through the process of uninstalling the file. It simply will not uninstall.

    Sentiment: Strong Sell

  • The day after XONE reported Q4, a couple analysts came out with cautious Hold rated reports and knocked the stock down. With reports like these, is it any wonder that the stock stayed down for only a day? It’s now back to higher levels. I can understand being cautious, given the lumpy quarters and difficulty in predicting timing of revenue recognition, but the company and their backlog is now showing signs of gaining traction. Caution is one thing, but the Canaccord “analyst “came out with a head line that said “show me story” His report is rated Hold, and price target remained $9. If he cared to look, he would see the company not only beat on top and bottom line, but in addition had an increased back log. That shows traction. The stock was well above $9 when he wrote his Hold report. What sense does that make? Seems like he is a transparent tool for the shorts. With the business coming together like it is now, the shorts are going to need better tools.

    Sentiment: Strong Buy

DXCM
77.46-0.13(-0.17%)Jun 24 4:00 PMEDT